Glucagon-like peptide-1 receptor agonists (GLP1-RA), are efficient drugs when used in the treatment of obesity [6–8], and seems to be a promising treatment of HO due to their multifaceted mechanism of action, which extends beyond the affected hypothalamic regions [9]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.